Introduction
Introduction

Cyclin A2 is unique among cyclins in that it is involved in both the G1/S and G2/M phases of the cell cycle and can activate key cyclin-dependent kinases (CDKs), such as CDK1 and CDK2. The cyclin A2-CDK complex plays an important role in the initiation of DNA replication and progression from S to M phase
. Overexpression of cyclin A2 has been reported in various malignant tumours such as lung, liver and stomach cancer [2] [3] [4] , and was an indicator of a poor prognosis. We previously reported that cyclin A2 overexpression was correlated with a poor prognosis in cases of endometrial carcinoma [5] . The association of cyclin A overexpression with aggressive clinicopathological phenotypes has been attributed mainly to enhanced growth potential. Although several studies have identified new functions of cyclin A2 other than regulation of the cell cycle, for example, DNA repair [6] and p53-independent anti-apoptosis [7] , the molecular mechanisms that explain these findings have not been fully elucidated.
Cisplatin, commonly used in combination with drugs such as adriamycin and taxanes, is a key drug for treating endometrial carcinoma [8] . Resistance to these drugs is a major therapeutic barrier. Recent studies have revealed that cisplatin-resistant carcinoma cells escaped from cisplatin-induced apoptosis by activating various survival mechanisms [9] . The activation of the phosphatidyl inositol-3-kinase (PI3K)-Akt pathway, a major constituent of the mitochondrial anti-apoptotic pathway, was reportedly one of the mechanisms by which carcinoma cells survive the effect of chemotherapeutic agents such as cisplatin [10] and paclitaxel [11] . In addition, the activation of the PI3K pathway is of great significance in endometrial carcinoma because this particular 
Immunohistochemistry
Immunostaining for periplakin was performed as described previously [5] . 
Western blot analysis
Proteins extracted from cells of sub-confluent cultures or surgically resected tissues were subjected to a Western blot analysis as described previously [13] . Blocking 
Chromatin immunoprecipitation assay
Cells were seeded at a density of 10 ϫ 10 6 in 150-mm culture dishes.
Chromatin fixation and purification were performed as described previously [14] . Fig. 1A and B) . Importantly, although the difference was not significant, the expression of cyclin A2 was stronger in chemotherapy-resistant tumours than in advanced-stage tumours (Fig. 1A and B) . The expression of cyclin E, another partner of CDK2, was also increased in carcinoma tissues, but was decreased in chemotherapy-refractory tumours as compared with advanced-stage tumours (Fig. 1B) . The expression of endogenous cyclin A2 varied in different endometrial carcinoma cell lines (Fig. 1C) (Fig. 2C) . Likewise, the IC50 for adriamycin was 1.91 and 0.88 M, respectively (Fig. 2D) . However, cyclin A2 did not have a significant effect on paclitaxel (Fig. 2E) . The silencing of cyclin A2 using siRNA reduced the cell viability after cisplatin treatment by 53% compared with the control HHUA-cycA cells (Fig. 2F, left) . To confirm this result, we performed the same silencing experiments using another endometrial carcinoma cell line, Hec-1A, which showed strong endogenous cyclin A2 expression (Fig. 1C) . Cisplatin reduced the viability of Hec-1A cells by 38% by abrogating cyclin A2 expression (Fig. 2F, right) (Fig. 3C, lower left) . In contrast, the HHUA-cycA tumour showed focal areas of necrosis (Fig. 3C, lower right) (Fig. 4A, leftmost two in the expression of cleaved caspase-3 by 38% (Fig. 4B) . Moreover, transfection of cyclin A2-specific siRNA prior to the cisplatin treatment significantly increased apoptosis (Fig. 4A, rightmost two bars) .
The effect of cyclin A2 on the PI3K pathway based on the detection of phosphorylated Akt (p-Akt) at different time points after cisplatin treatment was evaluated. HHUA-vec cells showed weak expression of p-Akt before cisplatin treatment (Fig. 4C, lane 1 (Fig. 4E, (Fig. 5A) . [17] , EMP1 [24] and CALB1 [26] . FGF9 [16] , PPL [21] and SORBS1 [23] are reportedly linked to the PI3K cascade. Among these candidate genes, we focused on PPL encoding periplakin, which was revealed to bind directly to Akt [21] . We demonstrated periplakin expression in all endometrial carcinoma cell lines (Fig. 5C, upper panel) and the expression of periplakin paralleled that of cyclin A2 (Fig. 5C, lower 
Fig. 2 Cyclin A2 enhanced the proliferation and cisplatin resistance in endometrial carcinoma HHUA cells in vitro. (A) The expression of cyclin A2 was increased in HHUA cells transfected with RC/CMV/cyclin A2 (HHUA-cycA) compared with vector-transfected HHUA cells (HHUA-vec) (left panel). Cyclin A2 silencing using cyclin A2-specific siRNA (40 nM) in HHUA-cycA cells resulted in reduced expression of cyclin A2 protein (right panel). (B) HHUAcycA cells (black line) showed increased proliferative activity compared with HHUA-vec cells (dashed line). Transfection of cyclin A2-specific siRNA (40 or 120 nM) reduced the proliferation of HHUA-cycA cells in a dose-dependent fashion in the WST-1 assay. (C-E) Dose-inhibitory curve for cisplatin (CDDP), adriamycin (ADM) and paclitaxel (PTX) in HHUA-vec and HHUA-cycA cells. Cyclin A2 increased the resistance to cisplatin and adriamycin, but not paclitaxel (*P Ͻ 0.05). (F) Silencing of cyclin A2 using siRNA (40 nM) reduced cisplatin resistance in HHUA-cycA (left panel) and Hec-1A (high endogenous cyclin A2 expression, right panel) cells. Viability was measured 5 days after cisplatin treatment using WST-1 assay. The viability was normalized with the value of control cells and expressed as relative survival (*P Ͻ 0.05). respectively (Fig. 4E, leftmost two bars). Pretreatment with wortmannin before the addition of cisplatin further reduced the viability of both HHUA-cycA and HHUA-vec cells; however importantly, the cyclin A2-induced cisplatin resistance in HHUA-cycA cells disappeared. In contrast, pretreatment with U0126 did not influence the cyclin A2-induced cisplatin resistance
To the extent that antibodies were commercially available, Western blotting was used to ascertain the expression of the protein transcripts of 5 of the 12 genes (Fig. 5B). The 12 included several genes for anti-apoptotic proteins such as AVEN
graph). Immunostaining demonstrated that periplakin was expressed in the cytoplasm of endometrial carcinoma cells (Fig. 5D, upper right and lower left). Periplakin is reportedly localized in cytoplasm or cell © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
05). (B) Subcutaneous inoculation of HHUA-cycA cells into nude mice followed by CDDP injection produced a larger mass (right) than that of HHUA-vec cells (left). (C) Haematoxylin and eosin staining of the mouse tumours from HHUA-vec (left) and HHUA-cycA cells (right). Cisplatin treatment resulted in extensive necrosis in HHUA-vec cell tumours (lower left) compared with HHUA-cycA cell tumours (lower right). Scale bars: 15 m.
surface [21] . We further demonstrated cytoplasmic localization of periplakin, where Akt exists, by immunofluorescent staining (Fig. 5D, lower right) . Immunoprecipitation revealed that periplakin was directly associated with Akt (Fig. 5E, upper  panel) and the Akt-bound fraction of periplakin in HHUA-cycA cells also increased significantly (Fig. 5E, lower panel) . The siRNA for periplakin decreased the expression of periplakin protein by 61% (Fig. 5F, top panel) , resulting in a reduction in basal p-Akt and cisplatin-treated p-Akt activities by 67 and 71%, respectively (Fig. 5F ).
Cyclin A2 promotes the transcription of periplakin via the Sp1-binding site in the periplakin promoter
The periplakin promoter reportedly spans from Ϫ382 bp to ϩ135 bp with three AP2 and one Sp1 (Ϫ277 bp) binding sites [27] (Fig. 6A) . To examine the expression mechanisms of periplakin, we performed a luciferase assay using a reporter that contained the region spanning from Ϫ409 bp to Ϫ182 bp, and possessed one crucial Sp1-binding site at Ϫ277 (Fig. 6A) enhanced the promoter's activity 3.8-fold compared with co-transfection of the vector plasmid (Fig. 6B) .
Cyclin A2-induced up-regulation of periplakin expression is mediated via the binding of Sp1, which is phosphorylated by cyclin A2, to the periplakin promoter
We then examined how cyclin A2 induced the expression of periplakin. Studies indicated that the cyclin A2-CDK complex phosphorylate Sp1, and the phosphorylated (activated) Sp1 binds to the promoter of target genes, resulting in elevated levels of transcription [14, 28] . The periplakin promoter reportedly possessed an Sp1 consensus sequence at bp Ϫ277 [27] . We developed a primer set targeting the Sp1-binding site (Fig. 6A) , and performed a ChIP (chromatin immunoprecipitation) assay using an antibody directed against Sp1 and chromatin obtained from HHUA-cycA and control cells. The ChIP assay showed that the recruitment of Sp1 to the promoter containing the Sp1-binding site at Ϫ277 was increased 3-fold in HHUA-cycA cells compared with control cells (Fig. 6C) . Furthermore, increased recruitment of Sp1 in HHUA-cycA cells was associated with enhanced recruitment of CBP/p300 and acetylated core histone H3, but not with histone deacetylase 1, in this region (Fig. 6C) . We could not detect significant differences in the binding of AP2 in this locus between the HHUA-cycA and HHUA-vec cells (Fig. 6C) .
As cyclin A2 and CDK are reported to induce the phosphorylation of Sp1 [14, [28] [29] [30] , we investigated the effect of cyclin A2 on the phosphorylation of Sp1. The overall expression of Sp1 protein did not differ between HHUA-cycA and control cells; however, the HHUAcycA cells showed a 4-fold increase in the phosphorylated (105-kD form) Sp1 (Fig. 6D) . Because Sp1 has a site for serine phosphorylation by cyclin A2-CDK complex [29] , we further evaluated the serine phosphorylation of Sp1 in HHUA-cycA using immunoprecipitation with anti-Sp1 antibody. Sp1 protein in the HHUA-cycA cells was more phosphorylated than that from control cells, which was confirmed by the treatment with calf alkaline phosphatase (Fig. 6E) . [31] . Therefore, it seems unreasonable for cyclin A to provide resistance rather than sensitivity to platinum. In this context, cyclin E, another partner of CDK2, reportedly enhanced proliferation and sensitized cancer cells to cisplatin [32] . To our knowledge, this is the first report to elucidate that cyclin A2 confers cisplatin resistance to human carcinoma cells.
Discussion
In the present study, we demonstrated that (i ) endometrial carcinoma tissues refractory to chemotherapy had higher levels of cyclin A2 than other tissue types, (ii ) the increased expression of endogenous cyclin A2 protein was correlated with resistance to cisplatin in endometrial carcinoma cell lines and (iii ) forced expression of cyclin A2 in endometrial carcinoma HHUA cells increased not only growth activity but also cisplatin resistance in vitro and in vivo. These results clearly indicated that the expression of cyclin A2 conferred the resistance to cisplatin on endometrial carcinoma cells. Cyclins are known to be expressed in the respective phase of the cell cycle, and cells expressing cyclin D, E or A are generally considered to be in the G1/S phase. In addition, platinum agents are thought to target cells in the G1/S phase
The present study also revealed that cyclin A2-induced cisplatin resistance is caused by the suppression of drug-induced (i.e. cisplatin-induced) apoptosis. In addition, we elucidated that the cyclin A2-mediated reduction in apoptosis was because of and cytidylyltransferase-␣ genes [28] . We also demonstrated that the enhanced recruitment of Sp1 to the specific promoter was associated with increased recruitment of CBP/p300. The CBP/p300 coactivator protein, which enhances transcription through histone acetyltransferase activity, was reportedly associated with Sp1 and promoted transcription of various genes such as the p21 [35] and tumour necrosis factor-␣ [36] 
